Guan Xuehao, Zhang Rui, Zhang Guangfang, Wang Jian, Wang Shuguang, Liu Baoshan* and Zhang Aiyuan*
Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor, played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation. In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional antihypertensive drugs (mainly including angiotensin receptor blockers or amlodipine), Sacubitril/Valsartan was firmly effective and safe. Thus, we deduce that Sacubitril/Valsartan’ indication for hypertension will be paid more attention and may be included in guideline for hypertension soon.
Published Date: 2022-08-29; Received Date: 2022-08-01
